Gamida Cell launches severe aplastic anemia trial
Gamida Cell said today that the first patient has been transplanted in a study of its CordIn product for patients with severe aplastic anemia or hypoplastic myelodysplastic syndrome. The product is designed for patients with rare genetic diseases who have no fully-matched donors for a bone marrow transplantation. Gamida Cell said it is also evaluating its CordIn therapy for patients with sickle cell disease. Get the full story at our sister site, Drug Delivery Business News. The post Gamida Cell launches severe aplastic anemia trial appeared first on MassDevice.
Authors: Copur MS, Wurdeman JM, Nelson D, Ramaekers R, Gauchan D, Crockett D Abstract Solid tumors involving glandular organs express mucin glycoprotein which is eventually shed into the circulation. As aresult these proteins can easily be measured in the serum and be used as potential tumor markers. The most commonly used tumor markers for breast cancer are CA 27-29 and CA 15-3, which both measure the glycoprotein product of the mucin-1 (MUC1) gene. CA 27-29 has been approved by the US Food and Drug Administration for monitoring disease activity in breast cancer patients. Most oncology clinical practice guidelines...
Authors: Omi Y, Horiuchi K, Haniu K, Tokura M, Nagai E, Isozaki O, Nagashima Y, Okamoto T Abstract Primary hyperparathyroidism is the most common hormonal manifestation associated with multiple endocrine neoplasia 1 (MEN1). It is generally caused by parathyroid hyperplasia, and parathyroid carcinoma is rare. Here, we report a case of MEN1 with parathyroid carcinoma in two parathyroid glands causing primary hyperparathyroidism. A 40-year-old man with primary hyperparathyroidism due to MEN1 underwent a total parathyroidectomy. His corrected calcium and intact PTH (i-PTH) serum levels were 10.8 mg/dL and 203 pg/mL, re...
Authors: Reible B, Schmidmaier G, Prokscha M, Moghaddam A, Westhauser F Abstract Bone defect treatment belongs to the most challenging fields in orthopedic surgery and requires the well-coordinated application of mesenchymal stem cells (MSC) and differentiation factors. MSC isolated from reaming material (RMSC) and iliac crest (BMSC) in combination with bone morphogenetic protein-7 (BMP-7) and insulin-like growth factor-1 (IGF-1) have been used. The short half-life of both factors limit their applications: a burst release of the factor can probably not induce sustainable differentiation. We stimulated MSC in osteog...
A British surgeon has admitted assaulting two patients by burning his initials into their livers during transplant operations
n Maître As pluripotent stem cells become primed to give rise to all bodily cell types, they begin to form the amniotic cavity in which the mammalian fetus will grow. A checkpoint that gates this transition has now been identified.
Conditions: Megaloblastic Anemia Nos; Pernicious Anemia Intervention: Drug: Hydroxocobalamin 10,000mcg, Thiamin 100mg, Pyridoxine 50mg Sponsor: Hospital Universitario Dr. Jose E. Gonzalez Recruiting
Conditions: Allogeneic Disease; GVH - Graft Versus Host Reaction; GVHD, Acute; Stem Cell Transplant Complications Interventions: Drug: Methotrexate; Drug: Placebo Sponsor: Assistance Publique - Hôpitaux de Paris Not yet recruiting
Conditions: Hemorrhagic Stroke; Intracerebral Hemorrhage Intervention: Biological: MSC Sponsor: Mayo Clinic Recruiting
Condition: Liver Transplantation Intervention: Sponsors: Assistance Publique - Hôpitaux de Paris; Agence de La Biomédecine Active, not recruiting
We describe a case of SCD, in which a patient with high HbF level presented at a very late age (27 years old). We presume the patient’s inherently elevated HbF levels were able to compensate for the hypoxic episodes associated with SCD. The onset of symptoms was delayed as a result of elevated HbF levels.